niacinamide has been researched along with Cystadenocarcinoma, Mucinous in 1 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inaba, K | 1 |
| Oda, K | 1 |
| Aoki, K | 1 |
| Sone, K | 1 |
| Ikeda, Y | 1 |
| Miyasaka, A | 1 |
| Kashiyama, T | 1 |
| Fukuda, T | 1 |
| Makii, C | 1 |
| Arimoto, T | 1 |
| Wada-Hiraike, O | 1 |
| Kawana, K | 1 |
| Yano, T | 1 |
| Osuga, Y | 1 |
| Fujii, T | 1 |
1 other study available for niacinamide and Cystadenocarcinoma, Mucinous
| Article | Year |
|---|---|
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug | 2016 |